Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)

07 Apr 20264 min read0 viewsINTERVENTIONAL Trial

GIST

RECRUITING · INTERVENTIONAL · TREATMENT study · Advanced Clear Cell Renal Carcinoma (Ccrcc) · Phase 1 · Enrollment 100 · Sponsor: National Cancer Institute (NCI)

Clinical Editorial

Summary

ClinicalTrials.gov published a clinical update in Oncology on 07 Apr 2026. The item focuses on Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC). Open the detail page to review the full original feed content.